Report Summary
"Fragile X syndrome (FXS)- Market Insights, Epidemiology and Market Forecast 2028" report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology. It highlights the existing treatment patterns, potential upcoming drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends, and drug uptake during the study period from 2016-2028.
Market Segment by Countries, covering:
United States
EU5 (Germany, France, Italy, Spain and the United Kingdom)
Japan
Study Period: 2016-2028
Fragile X syndrome (FXS) Understanding and Treatment Algorithm
The report provides the in depth analysis of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. The comprehensive details about treatment algorithms and treatment guidelines for Fragile X syndrome (FXS)in the US, Europe, and Japan are also provided in the report.
Fragile X syndrome (FXS) Epidemiology
This section provide the insights about historical and current patient pool and forecasted trend for 7 major markets. It takes in to account the analysis of numerous studies, survey reports as well as KOL’s views which helps to recognize the factors behind the current and forecasted trends, diagnosed and treatable patient pool along with assumptions undertaken.
Fragile X syndrome (FXS) Product Profiles & Analysis
This part of the Fragile X syndrome (FXS) report encloses the detailed analysis of marketed drugs and Phase III and late Phase II pipeline drugs. It provides the key cross competition which evaluates the drugs on several parameters including, safety & efficacy results, mechanism of action, route, launch dates and designations. This section also covers the market intelligence and tracking of latest happenings, agreements and collaborations, approvals, patent details and other major breakthroughs.
Fragile X syndrome (FXS) Market Outlook
The Fragile X syndrome (FXS) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment analyses the market trend of each marketed drug and late-stage pipeline drugs. This is done by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders . The calculated market data is presented with relevant tables and graphs to give a clear view of the market at first sight.
Fragile X syndrome (FXS) Market Share by Therapies
This section focusses on the rate of uptake of the potential drugs recently launched or will be launched in the market during the study period from 2016-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This information also helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It provides the comparison of the drugs on the basis of market share and size. This analysis helps in investigating factors important in market uptake and in making financial as well as regulatory decisions.
Fragile X syndrome (FXS) Report Insights
Patient Population in Fragile X syndrome (FXS)
Therapeutic Approaches in Fragile X syndrome (FXS)
Fragile X syndrome (FXS) Pipeline Analysis
Fragile X syndrome (FXS) Market Size and Trends
Fragile X syndrome (FXS) Market Opportunities
Impact of upcoming Therapies in Fragile X syndrome (FXS)
Fragile X syndrome (FXS) Report Key Strengths
10 Year Forecast
7MM Coverage
Epidemiology Segmentation
Drugs Uptake
Highly Analyzed Market
Key Cross Competition
Fragile X syndrome (FXS) Report Assessment
Current Treatment Practices in Fragile X syndrome (FXS)
Unmet Needs in Fragile X syndrome (FXS)
Detailed Fragile X syndrome (FXS) Pipeline Product Profiles
Market Attractiveness
Market Drivers and Barriers
Key Benefits
This report will help to develop Business Strategies by understanding the trends shaping and driving the Fragile X syndrome (FXS) market
Organize sales and marketing efforts by identifying the best opportunities for Fragile X syndrome (FXS) market
To understand the future market competition in the Fragile X syndrome (FXS) market.
Note: We understand the needs of the rapidly changing market and is helping the client by providing the most up to date Report. It usually takes 4-5 days to deliver this kind of Report. The report coverage will depend on the availability of the data.
Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Interested in this report?
Get your sample now!
Table of Contents
1 Key Insights
2 Fragile X syndrome (FXS) Market Overview at a Glance
2.1 Market Share (%) Distribution of Fragile X syndrome (FXS) in 2018
2.2 Market Share (%) Distribution of Fragile X syndrome (FXS) in 2028
3 Fragile X syndrome (FXS): Disease Background and Overview
3.1 Introduction
3.2 Symptoms
3.3 Etiology
3.4 Risk Factor
3.5 Pathophysiology
3.6 Diagnosis
3.7 Treatment
4 Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Fragile X syndrome (FXS) in 7MM
4.3. Total Prevalent Patient Population of Fragile X syndrome (FXS) in 7MM – By Countries
5 Epidemiology of Fragile X syndrome (FXS) by Countries (2016-2028)
5.1 United States- Epidemiology (2016-2028)
5.1.1 Assumptions and Rationale
5.1.2 Prevalent/Incident Cases of Fragile X syndrome (FXS) in the United States
5.1.3 Sub-Type Specific cases of Fragile X syndrome (FXS) in the United States
5.1.4 Sex- Specific Cases of Fragile X syndrome (FXS) in the United States
5.1.5 Diagnosed Cases of Fragile X syndrome (FXS) in the United States
5.1.6 Treatable Cases of Fragile X syndrome (FXS) in the United States
5.2 EU5 Countries
5.2.1 Germany
5.2.1.1 Assumptions and Rationale
5.2.1.2 Prevalent/Incident Cases of the of Fragile X syndrome (FXS) in the Germany
5.2.1.3 Sub-Type Specific cases of Fragile X syndrome (FXS) in the Germany
5.2.1.4 Sex- Specific Cases of the Fragile X syndrome (FXS) in the Germany
5.2.1.5 Diagnosed Cases of the Fragile X syndrome (FXS) in the Germany
5.2.1.6 Treatable Cases of the Fragile X syndrome (FXS)
5.2.2 France
5.2.2.1 Assumptions and Rationale
5.2.2.2 Prevalent/Incident Cases of the of Fragile X syndrome (FXS) in the France
5.2.2.3 Sub-Type Specific cases of Fragile X syndrome (FXS) in the France
5.2.2.4 Sex- Specific Cases of the Fragile X syndrome (FXS) in the France
5.2.2.5 Diagnosed Cases of the Fragile X syndrome (FXS) in the France
5.2.2.6 Treatable Cases of the Fragile X syndrome (FXS)
5.2.3 Italy
5.2.3.1 Assumptions and Rationale
5.2.3.2 Prevalent/Incident Cases of the of Fragile X syndrome (FXS) in the Italy
5.2.3.3 Sub-Type Specific cases of Fragile X syndrome (FXS) in the Italy
5.2.3.4 Sex- Specific Cases of the Fragile X syndrome (FXS) in the Italy
5.2.3.5 Diagnosed Cases of the Fragile X syndrome (FXS) in the Italy
5.2.3.6 Treatable Cases of the Fragile X syndrome (FXS)
5.2.4 Spain
5.2.4.1 Assumptions and Rationale
5.2.4.2 Prevalent/Incident Cases of the of Fragile X syndrome (FXS) in the Spain
5.2.4.3 Sub-Type Specific cases of Fragile X syndrome (FXS) in the Spain
5.2.4.4 Sex- Specific Cases of the Fragile X syndrome (FXS) in the Spain
5.2.4.5 Diagnosed Cases of the Fragile X syndrome (FXS) in the Spain
5.2.4.6 Treatable Cases of the Fragile X syndrome (FXS)
5.2.5 United Kingdom
5.2.5.1 Assumptions and Rationale
5.2.5.2 Prevalent/Incident Cases of the of Fragile X syndrome (FXS) in the United Kingdom
5.2.5.3 Sub-Type Specific cases of Fragile X syndrome (FXS) in the United Kingdom
5.2.5.4 Sex- Specific Cases of the Fragile X syndrome (FXS) in the United Kingdom
5.2.5.5 Diagnosed Cases of the Fragile X syndrome (FXS) in the United Kingdom
5.2.5.6 Treatable Cases of the Fragile X syndrome (FXS)
5.3 Japan
5.3.1 Assumptions and Rationale
5.3.2 Prevalent/Incident Cases of the of Fragile X syndrome (FXS) in the Japan
5.3.3 Sub-Type Specific cases of Fragile X syndrome (FXS) in the Japan
5.3.4 Sex- Specific Cases of the Fragile X syndrome (FXS) in the Japan
5.3.5 Diagnosed Cases of the Fragile X syndrome (FXS) in the Japan
5.3.6 Treatable Cases of the Fragile X syndrome (FXS)
6 Current Treatment & Medical practices
6.1 Treatment Algorithm
6.2 Treatment Guidelines
7 Unmet Needs
8 Marketed Product
8.1 Drug A: Company 1
8.1.1 Drug Description
8.1.2 Mechanism of Action
8.1.3 Clinical Trials Details
8.1.4 Advantages & Disadvantages
8.1.5 Safety and Efficacy
8.1.6 Product Profile
8.2 Drug B: Company 2
8.2.1 Drug Description
8.2.2 Mechanism of Action
8.2.3 Clinical Trials Details
8.2.4 Advantages & Disadvantages
8.2.5 Safety and Efficacy
8.2.6 Product Profile
8.3 Drug C: Company 3
8.3.1 Drug Description
8.3.2 Mechanism of Action
8.3.3 Clinical Trials Details
8.3.4 Advantages & Disadvantages
8.3.5 Safety and Efficacy
8.3.6 Product Profile
8.4 Drug D: Company 4
8.4.1 Drug Description
8.4.2 Mechanism of Action
8.4.3 Clinical Trials Details
8.4.4 Advantages & Disadvantages
8.4.5 Safety and Efficacy
8.4.6 Product Profile
8.5 Drug E: Company 5
8.5.1 Drug Description
8.5.2 Mechanism of Action
8.5.3 Clinical Trials Details
8.5.4 Advantages & Disadvantages
8.5.5 Safety and Efficacy
8.5.6 Product Profile
8.6 : Company 6
8.6.1 Drug Description
8.6.2 Mechanism of Action
8.6.3 Clinical Trials Details
8.6.4 Advantages & Disadvantages
8.6.5 Safety and Efficacy
8.6.6 Product Profile
8.7 : Company 7
8.7.1 Drug Description
8.7.2 Mechanism of Action
8.7.3 Clinical Trials Details
8.7.4 Advantages & Disadvantages
8.7.5 Safety and Efficacy
8.7.6 Product Profile
8.8 : Company 8
8.8.1 Drug Description
8.8.2 Mechanism of Action
8.8.3 Clinical Trials Details
8.8.4 Advantages & Disadvantages
8.8.5 Safety and Efficacy
8.8.6 Product Profile
9 Emerging Drugs
9.1 Key Cross Competition
9.2 Emerging company
9.2.1 Emerging Drug A: Company 10
9.2.1.1 Other Development Activities
9.2.1.2 Clinical Development
9.2.1.3 Clinical Trials Information
9.2.1.4 Safety and Efficacy
9.2.1.5 Advantages and Disadvantages
9.2.1.6 Product Profile
9.2.2 Emerging Drug B: Company 11
9.2.2.1 Other Development Activities
9.2.2.2 Clinical Development
9.2.2.3 Clinical Trials Information
9.2.2.4 Safety and Efficacy
9.2.2.5 Advantages and Disadvantages
9.2.2.6 Product Profile
9.2.3 Emerging Drug C: Company 12
9.2.3.1 Other Development Activities
9.2.3.2 Clinical Development
9.2.3.3 Clinical Trials Information
9.2.3.4 Safety and Efficacy
9.2.3.5 Advantages and Disadvantages
9.2.3.6 Product Profile
9.2.4 Emerging Drug D: Company 13
9.2.4.1 Other Development Activities
9.2.4.2 Clinical Development
9.2.4.3 Clinical Trials Information
9.2.4.4 Safety and Efficacy
9.2.4.5 Advantages and Disadvantages
9.2.4.6 Product Profile
9.2.5 Emerging Drug E: Company 14
9.2.5.1 Other Development Activities
9.2.5.2 Clinical Development
9.2.5.3 Clinical Trials Information
9.2.5.4 Safety and Efficacy
9.2.5.5 Advantages and Disadvantages
9.2.5.6 Product Profile
10 7MM Market Analysis
10.1 7MM Market Size of Fragile X syndrome (FXS)
10.2 7MM Percentage Share of Drugs Marketed for Fragile X syndrome (FXS)
10.3 7MM Market Sales of Fragile X syndrome (FXS) by Products
11 The United States Market Outlook
11.1 Market Size of Fragile X syndrome (FXS) in United States
11.2 Percentage Share of Drugs Marketed for Fragile X syndrome (FXS) in United States
11.3 Market Sales of Fragile X syndrome (FXS) by Products in United States
11.4 Analysis of Upcoming Therapies and Impact on the Market
12 EU5 Countries Market Outlook
12.1 Market Size of Fragile X syndrome (FXS) in EU5
12.2 Market Size of Fragile X syndrome (FXS) in Germany
12.2.1 Market Size of Fragile X syndrome (FXS) in Germany
12.2.2 Percentage Share of Drugs Marketed for Fragile X syndrome (FXS) in Germany
12.2.3 Market Sales of Fragile X syndrome (FXS) by Products in Germany
12.2.4 Analysis of Upcoming Therapies and Impact on the Market
12.3 Market Size of Fragile X syndrome (FXS) in France
12.3.1 Market Size of Fragile X syndrome (FXS) in France
12.3.2 Percentage Share of Drugs Marketed for Fragile X syndrome (FXS) in France
12.3.3 Market Sales of Fragile X syndrome (FXS) by Products in France
12.3.4 Analysis of Upcoming Therapies and Impact on the Market
12.4 Market Size of Fragile X syndrome (FXS) in Italy
12.4.1 Market Size of Fragile X syndrome (FXS) in Italy
12.4.2 Percentage Share of Drugs Marketed for Fragile X syndrome (FXS) in Italy
12.4.3 Market Sales of Fragile X syndrome (FXS) by Products in Italy
12.4.4 Analysis of Upcoming Therapies and Impact on the Market
12.5 Market Size of Fragile X syndrome (FXS) in Spain
12.5.1 Market Size of Fragile X syndrome (FXS) in Spain
12.5.2 Percentage Share of Drugs Marketed for Fragile X syndrome (FXS) in Spain
12.5.3 Market Sales of Fragile X syndrome (FXS) by Products in Spain
12.5.4 Analysis of Upcoming Therapies and Impact on the Market
12.6 Market Size of Fragile X syndrome (FXS) in United Kingdom
12.6.1 Market Size of Fragile X syndrome (FXS) in United Kingdom
12.6.2 Percentage Share of Drugs Marketed for Fragile X syndrome (FXS) in United Kingdom
12.6.3 Market Sales of Fragile X syndrome (FXS) by Products in United Kingdom
12.6.4 Analysis of Upcoming Therapies and Impact on the Market
13 The Japan Market Outlook
13.1 Market Size of Fragile X syndrome (FXS) in Japan
13.2 Percentage Share of Drugs Marketed for Fragile X syndrome (FXS) in Japan
13.3 Market Sales of Fragile X syndrome (FXS) by Products in Japan
13.4 Analysis of Upcoming Therapies and Impact on the Market
14 Cost Analysis of Fragile X syndrome (FXS)
15 Generic Competition in Fragile X syndrome (FXS) Market
16 Market Drivers
17 Market Barriers
18 Report Methodology
18.1 Methodology/Research Approach
18.2 Data Source
18.2.1 Secondary Sources
18.2.2 Primary Sources
List of Figures
Figure Market Share (%) Distribution of Fragile X syndrome (FXS) in 2019
Figure Market Share (%) Distribution of Fragile X syndrome (FXS) in 2028
Figure Total Prevalent/Incident Cases of the Fragile X syndrome (FXS) in 7MM
Figure Total Prevalent/Incident Cases of the Fragile X syndrome (FXS) in 7MM
Figure Prevalent/Incident Cases of the Fragile X syndrome (FXS) in United States (2016-2028)
Figure Sub-Type Specific cases of the Fragile X syndrome (FXS) in United States (2016-2028)
Figure Sex- Specific Cases of the Fragile X syndrome (FXS) in United States (2016-2028)
Figure Diagnosed Cases of the Fragile X syndrome (FXS) in United States (2016-2028)
Figure Treatable Cases of the Fragile X syndrome (FXS) in United States (2016-2028)
Figure Prevalent/Incident Cases of the Fragile X syndrome (FXS) in Germany (2016-2028)
Figure Sub-Type Specific cases of the Fragile X syndrome (FXS) in Germany (2016-2028)
Figure Sex- Specific Cases of the Fragile X syndrome (FXS) in Germany (2016-2028)
Figure Diagnosed Cases of the Fragile X syndrome (FXS) in Germany (2016-2028)
Figure Treatable Cases of the Fragile X syndrome (FXS) in Germany (2016-2028)
Figure Prevalent/Incident Cases of the Fragile X syndrome (FXS) in France (2016-2028)
Figure Sub-Type Specific cases of the Fragile X syndrome (FXS) in France (2016-2028)
Figure Sex- Specific Cases of the Fragile X syndrome (FXS) in France (2016-2028)
Figure Diagnosed Cases of the Fragile X syndrome (FXS) in France (2016-2028)
Figure Treatable Cases of the Fragile X syndrome (FXS) in France (2016-2028)
Figure Prevalent/Incident Cases of the Fragile X syndrome (FXS) in Italy (2016-2028)
Figure Sub-Type Specific cases of the Fragile X syndrome (FXS) in Italy (2016-2028)
Figure Sex- Specific Cases of the Fragile X syndrome (FXS) in Italy (2016-2028)
Figure Diagnosed Cases of the Fragile X syndrome (FXS) in Italy (2016-2028)
Figure Treatable Cases of the Fragile X syndrome (FXS) in Italy (2016-2028)
Figure Prevalent/Incident Cases of the Fragile X syndrome (FXS) in Spain (2016-2028)
Figure Sub-Type Specific cases of the Fragile X syndrome (FXS) in Spain (2016-2028)
Figure Sex- Specific Cases of the Fragile X syndrome (FXS) in Spain (2016-2028)
Figure Diagnosed Cases of the Fragile X syndrome (FXS) in Spain (2016-2028)
Figure Treatable Cases of the Fragile X syndrome (FXS) in Spain (2016-2028)
Figure Prevalent/Incident Cases of the Fragile X syndrome (FXS) in United Kingdom (2016-2028)
Figure Sub-Type Specific cases of the Fragile X syndrome (FXS) in United Kingdom (2016-2028)
Figure Sex- Specific Cases of the Fragile X syndrome (FXS) in United Kingdom (2016-2028)
Figure Diagnosed Cases of the Fragile X syndrome (FXS) in United Kingdom (2016-2028)
Figure Treatable Cases of the Fragile X syndrome (FXS) in United Kingdom (2016-2028)
Figure Prevalent/Incident Cases of the Fragile X syndrome (FXS) in Japan (2016-2028)
Figure Sub-Type Specific cases of the Fragile X syndrome (FXS) in Japan (2016-2028)
Figure Sex- Specific Cases of the Fragile X syndrome (FXS) in Japan (2016-2028)
Figure Diagnosed Cases of the Fragile X syndrome (FXS) in Japan (2016-2028)
Figure Treatable Cases of the Fragile X syndrome (FXS) in Japan (2016-2028)
Figure Treatment algorithm for Fragile X syndrome (FXS)
Figure Diagnosis and Therapy selection
Figure Unmet Needs of Fragile X syndrome (FXS) Disease
Figure 7MM- Market Size of Fragile X syndrome (FXS) in USD MM (2016-2028)
Figure 7MM- Market Share Fragile X syndrome (FXS) by Therapies in USD MM (2016-2028)
Figure US Market Size of Fragile X syndrome (FXS) in USD, Million (2016-2028)
Figure United States-Market Share Fragile X syndrome (FXS) by Therapies in USD MM (2016-2028)
Figure United States-Market Sales of Fragile X syndrome (FXS) by Therapies in USD MM (2017-2028)
Figure EU5 Market Size of Fragile X syndrome (FXS) (MS) in USD, Million (2016-2028)
Figure Germany Market Size of Fragile X syndrome (FXS) in USD, Million (2016-2028)
Figure Germany -Market Share Fragile X syndrome (FXS) by Therapies in USD MM (2016-2028)
Figure Germany -Market Sales of Fragile X syndrome (FXS) by Therapies in USD MM (2017-2028)
Figure France Market Size of Fragile X syndrome (FXS) in USD, Million (2016-2028)
Figure France -Market Share Fragile X syndrome (FXS) by Therapies in USD MM (2016-2028)
Figure France -Market Sales of Fragile X syndrome (FXS) by Therapies in USD MM (2017-2028)
Figure Italy Market Size of Fragile X syndrome (FXS) in USD, Million (2016-2028)
Figure Italy -Market Share Fragile X syndrome (FXS) by Therapies in USD MM (2016-2028)
Figure Italy -Market Sales of Fragile X syndrome (FXS) by Therapies in USD MM (2017-2028)
Figure Spain Market Size of Fragile X syndrome (FXS) in USD, Million (2016-2028)
Figure Spain -Market Share Fragile X syndrome (FXS) by Therapies in USD MM (2016-2028)
Figure Spain -Market Sales of Fragile X syndrome (FXS) by Therapies in USD MM (2017-2028)
Figure United Kingdom Market Size of Fragile X syndrome (FXS) in USD, Million (2016-2028)
Figure United Kingdom -Market Share Fragile X syndrome (FXS) by Therapies in USD MM (2016-2028)
Figure United Kingdom -Market Sales of Fragile X syndrome (FXS) by Therapies in USD MM (2017-2028)
Figure Japan Market Size of Fragile X syndrome (FXS) in USD, Million (2016-2028)
Figure Japan -Market Share Fragile X syndrome (FXS) by Therapies in USD MM (2016-2028)
